Drug intelligence / Profile preview

5-iodotubercidin

Development stage
Preclinical
Lead developer
Joslin Diabetes Center
Modality
Small Molecules
Administration
Intravenous (for Research/animal Studies), Not Clinically Established For Human Use[7]
01

Overview

5-Iodotubercidin is a synthetic purine nucleoside analog and a potent small molecule inhibitor of adenosine kinase (ADK), with an IC50 of approximately 26 nM. It acts as an ATP mimetic and inhibits ADK, leading to increased extracellular adenosine levels. This compound also inhibits other kinases, including casein kinase 1 (CK1), haspin, insulin receptor kinase, and leucine-rich repeat kinase 2 (LRRK2). Mechanistically, it can induce DNA damage and apoptosis in tumor cells by activating the ATM/p53 pathway. Preclinical studies have shown anti-tumor activity in models such as insulinoma. Additionally, radiolabeled forms have been explored for imaging ADK expression in vivo. It is primarily used as a research tool; there are no approved clinical indications[1][4][9].

Other names
5'-iodotubericidinIODOTUBERCIDIN7-I-7-Deaza-ArIodotubercidin, Itu5-Iodo-Tubercidine
02

Targets

CK1α (Casein kinase I alpha)GSG2 (Germ cell associated 2, haspin)ADK (Adenosine kinase)

Beyond the preview

Go deeper on 5-iodotubercidin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-iodotubercidin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call